FibroGen, Inc (FGEN) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.196 Good, Dan, thank you for standing by. Welcome to FibroGen first quarter 2025 earnings 00:00:04.196 -- 00:00:08.281 conference call. At this time, all participants are on a listen-only mode. 00:00:08.281 -- 00:00:11.185 After the speaker's presentation, there'll be a question and answer session. 00:00:11.185 -- 00:00:14.669 To ask a question during the session, you'll need to press star one one on your telephone. 00:00:14.669 -- 00:00:17.573 You will then hear an automated message advising your hand is raised. 00:00:17.573 -- 00:00:20.436 To withdraw your question, please press star one one again. 00:00:20.436 -- 00:00:23.000 Please be advised today's conference is being recorded. 00:00:23.000 -- 00:00:25.323 I would now like to hand the conference over to your speaker today. 00:00:25.323 -- 00:00:28.046 Joanne Greller, please go ahead. 00:00:28.046 -- 00:00:30.676 Thank you, operator. Good afternoon, everyone. 00:00:30.676 -- 00:00:35.863 Thank you for joining today to discuss Fibrogen's first quarter 2025 financial 00:00:35.863 -- 00:00:40.328 and business results. I'm Joanne Greller from LifeSci Advisors. 00:00:40.328 -- 00:00:45.415 Joining me on today's call are Thayne Wettig, our Chief Executive Officer, and David 00:00:45.415 -- 00:00:50.502 DeLucia, our Chief Financial Officer. Following the prepared remarks, we will 00:00:50.502 -- 00:00:55.108 open the call to your questions. I would like to remind you that remarks made on today's 00:00:55.108 -- 00:00:59.093 call include forward listening statements about Fibrogen. 00:00:59.093 -- 00:01:04.320 Such statements may include, but are not limited to, our collaborations with AstraZeneca 00:01:04.320 -- 00:01:09.788 and Acelis, financial guidance, initiation, enrollment, design,...